Plasma protein binding

How to avoid costly mistakes during Medicare open enrollment

Retrieved on: 
Thursday, October 12, 2023
Medicare Part D, Pharmacy, Inflation Reduction Act of 2022, Medicare, Plasma protein binding, AEP, IRA, Inflation, Federation, Part, FAQ, Health policy, Research, Health insurance

Today, medicareresources.org released three tips to help consumers avoid costly mistakes during Medicare open enrollment, which runs from Oct. 15 to Dec. 7.

Key Points: 
  • Today, medicareresources.org released three tips to help consumers avoid costly mistakes during Medicare open enrollment, which runs from Oct. 15 to Dec. 7.
  • “Doing a little research during open enrollment can go a long way toward ensuring you don’t pay too much in premiums or miss cost-saving opportunities.”
    Here are more strategies to keep in mind:
    Compare your options during Medicare open enrollment.
  • Most Medicare beneficiaries do not switch plans or even review their options, despite being bombarded by advertisements for different plans during open enrollment.
  • The site provides an overview of the basics of Medicare coverage options , enrollment and eligibility ; coverage FAQs ; state-specific Medicare information ; and a glossary of Medicare terms .

Inmar Intelligence Hosts Drug Take-Back Event In Winston-Salem To Safeguard Public Health And Environment

Retrieved on: 
Thursday, October 12, 2023
Partnership, Health, Forsyth County, Drinking water, Public, Risk, Safety, Plasma protein binding, Drug, Opioid, Water, Environment, Regulation, Psychological abuse, Drug Enforcement Administration, Child, Novant Health, Patient, DEA, Pharmaceutical industry, Dietary supplement, Medical device, Poultry farming

The National Prescription Drug Take-Back Day, endorsed by the Drug Enforcement Administration (DEA), focuses on enhancing public safety and health by eliminating the risk of medication misuse and opioid addiction.

Key Points: 
  • The National Prescription Drug Take-Back Day, endorsed by the Drug Enforcement Administration (DEA), focuses on enhancing public safety and health by eliminating the risk of medication misuse and opioid addiction.
  • "We are extremely pleased to continue our partnership with Novant Health and the Forsyth County Sheriff's Office for our upcoming Drug Take-Back event at Bolton Elementary School," said Ashley Schmidt, Vice President of Regulatory and Compliance, Inmar Intelligence.
  • “Novant Health is excited to partner with Inmar Intelligence to provide our patients and community with this safe, convenient medication disposal opportunity.
  • Dispose of your unused and expired medications responsibly at the Drug Take-Back event on October 28th, and together, we can protect our loved ones and our environment.

Silo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSD

Retrieved on: 
Wednesday, October 11, 2023
Post-traumatic stress disorder, Therapy, PTSD, Biomarker, SILO, Plasma protein binding, Anxiety, Columbia University, Stress-related disorders, Research, Pharmaceutical industry

ENGLEWOOD CLIFFS, NJ, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced plans to initiate a human factor study of its targeted prophylactic treatment SPC-15 for the treatment of post-traumatic stress disorder (PTSD). The study will evaluate the human factor interface and usability of SPC-15’s intranasal formulation in combination with a nose-to-brain delivery mechanism.

Key Points: 
  • ENGLEWOOD CLIFFS, NJ, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced plans to initiate a human factor study of its targeted prophylactic treatment SPC-15 for the treatment of post-traumatic stress disorder (PTSD).
  • The study will evaluate the human factor interface and usability of SPC-15’s intranasal formulation in combination with a nose-to-brain delivery mechanism.
  • “The human factors study is an important step as we prepare and plan to enter the clinic with SPC-15 for the treatment of PTSD and stress-related disorders,” said Eric Weisblum, Chief Executive Officer of Silo Pharma.
  • Silo Pharma is conducting preclinical studies of SPC-15 in collaboration with Columbia University pursuant to a sponsored research agreement and option.

Galderma @ EADV 2023: Phase III Trials Demonstrate Nemolizumab’s Efficacy and Rapid Onset of Action in Atopic Dermatitis and Prurigo Nodularis

Retrieved on: 
Wednesday, October 11, 2023
Health, Managed Care, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, III, Multimedia, Journal of the European Academy of Dermatology and Venereology, Galderma, Atopic dermatitis, Prurigo nodularis, Mental health, Congress, Itch, Nemolizumab, Adolescence, IGA, Sleep, Skin, Plasma protein binding, Patient, Pharmaceutical industry, Dermatology, Venereology

Galderma announced positive data from three pivotal phase III trials in atopic dermatitis and prurigo nodularis – ARCADIA 1 and 2 and OLYMPIA 1, respectively.

Key Points: 
  • Galderma announced positive data from three pivotal phase III trials in atopic dermatitis and prurigo nodularis – ARCADIA 1 and 2 and OLYMPIA 1, respectively.
  • The late-breaking data were presented today at the 2023 European Academy of Dermatology and Venereology (EADV) congress in Berlin.
  • View the full release here: https://www.businesswire.com/news/home/20231011848851/en/
    “While atopic dermatitis and prurigo nodularis are distinct diseases, their commonality lies in the severe, persistent itch, which leads to poor quality sleep and negatively impacts mental health.
  • Statistically significant results at week 16 and earlier time points also show nemolizumab’s rapid onset of action on itch and sleep disturbance.

New National Survey by Curative Reveals Astonishing Failures of Traditional Employer-Sponsored Health Insurance Plans

Retrieved on: 
Tuesday, October 10, 2023
Health Insurance, Telemedicine, Virtual Medicine, Insurance, Human Resources, Pharmaceutical, Managed Care, General Health, Professional Services, Mental Health, Women, Hospitals, Men, LGBTQ+, Family, Consumer, Health, Telehealth, Absenteeism, Prescription, Research, Molina Healthcare, Ageing, MSA, Plasma protein binding, St. Louis Fed Financial Stress Index, Census, OOP, PPO, RIM, Workforce, Hispanic and Latino Americans, Face, Patient, Health insurance, Life insurance, Health care, Medical device, Curative

Curative Insurance Company recently unveiled the findings of a nationwide survey involving 2,500 Americans who are enrolled in employer-sponsored insurance plans*.

Key Points: 
  • Curative Insurance Company recently unveiled the findings of a nationwide survey involving 2,500 Americans who are enrolled in employer-sponsored insurance plans*.
  • Overall, these data underscore a health crisis for working Americans whose traditional, employer-sponsored plans fail to provide fundamental healthcare coverage.
  • The primary aim of this survey was to gain insights into the challenges individuals face with traditional health insurance plans.
  • 44% report their personal health has impacted their work performance; that statistic jumps to 65% for those in high deductible health plans.

Successful Launch of JVM's Next-Generation Automated Drug Dispensing System via High-End Robot Arm 'MENITH' in the European Market

Retrieved on: 
Monday, October 16, 2023
Online, Pharmacy, JVM, Hanmi Pharmaceutical, Development, Plasma protein binding, Automation, Soft drink

SEOUL, South Korea, Oct. 16, 2023 /PRNewswire/ -- A state-of-the-art, next-generation automated drug dispensing machine equipped with a robotic arm, independently developed by JVM, an affiliate of Hanmi Science, was successfully launched in the European market.

Key Points: 
  • SEOUL, South Korea, Oct. 16, 2023 /PRNewswire/ -- A state-of-the-art, next-generation automated drug dispensing machine equipped with a robotic arm, independently developed by JVM, an affiliate of Hanmi Science, was successfully launched in the European market.
  • Based on this contract, JVM will be able to expand its European business, which had been focused on entry-level models, to 'large-scale high-end models'.
  • MENITH is one of JVM's next-generation products that will lead the future pharmacy automation market.
  • It is also equipped with an automated inspection system, which minimizes the pharmacy dispensing process time and resources.

Agomab Receives FDA Fast Track Designation for AGMB-129 in Fibrostenosing Crohn’s Disease and Starts STENOVA Phase 2a Clinical Trial

Retrieved on: 
Thursday, October 5, 2023
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, GI, Anti-inflammatory, Fast track (FDA), FSCD, Food, Pharmacokinetics, Plasma protein binding, ALK5, MD, Safety, OH, Disease, TGF, Gastrointestinal tract, Therapy, Stenosis, NDA, Fast Track, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Fibrosis, STAR, Nutrition, Cleveland Clinic, Pharmaceutical industry

Agomab Therapeutics NV (‘Agomab’) today announced that it received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for AGMB-129 for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD).

Key Points: 
  • Agomab Therapeutics NV (‘Agomab’) today announced that it received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for AGMB-129 for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD).
  • In addition, Agomab has initiated its STENOVA Phase 2a clinical trial evaluating AGMB-129, an oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (TGF-βRI or ALK5), in patients with symptomatic FSCD.
  • AGMB-129 is the first drug candidate to receive FDA Fast Track Designation for the treatment of Fibrostenosing Crohn’s Disease.
  • The STENOVA Phase 2a clinical trial is a randomized, double-blind, placebo-controlled study in 36 patients with symptomatic FSCD.

South Rampart Pharma Receives U.S. FDA Fast Track Designation for SRP-001 for Acute Pain

Retrieved on: 
Thursday, October 12, 2023
Pain, Male, Priority review, Food, Female, Plasma protein binding, PAG, U.S. FDA, MD, Aes, Communication, Liver, PK, Safety, Western world, MAD, Vital signs, Paracetamol, FDA, White Light Rock & Roll Review, Collection, Accelerated approval (FDA), Kidney, NDA, Acute liver failure, Automated ECG interpretation, Fast Track, New Drug Application, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Volunteering, CNS, Patient, Pharmaceutical industry, Medical device

NEW ORLEANS, Oct. 12, 2023 /PRNewswire/ -- South Rampart Pharma, Inc. ("South Rampart" or the "Company"), a clinical-stage biopharmaceutical company targeting the safer treatment of pain, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company for SRP-001 for the treatment of acute pain. SRP-001 is a novel, first-in-class non-opioid analgesic that activates pain signaling pathways in the midbrain's periaqueductal grey (PAG) region without liver and kidney toxicities. The Fast Track designation facilitates the development and expedites the review of new therapies for serious conditions, aiming to bring important new drugs to patients earlier and address unmet medical needs.

Key Points: 
  • The Fast Track designation accelerates SRP-001's path to U.S. FDA submission for the treatment of acute pain
    Enhanced time-to-market delivers a therapeutic alternative to habit-forming opioids and acetaminophen, the leading cause of acute liver failure in the U.S.
    NEW ORLEANS, Oct. 12, 2023 /PRNewswire/ -- South Rampart Pharma, Inc. ("South Rampart" or the "Company"), a clinical-stage biopharmaceutical company targeting the safer treatment of pain, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company for SRP-001 for the treatment of acute pain.
  • SRP-001 is a novel, first-in-class non-opioid analgesic that activates pain signaling pathways in the midbrain's periaqueductal grey (PAG) region without liver and kidney toxicities.
  • The Fast Track designation facilitates the development and expedites the review of new therapies for serious conditions, aiming to bring important new drugs to patients earlier and address unmet medical needs.
  • "In the CNS and pain space, Fast Track designation for SRP-001 isn't just a regulatory milestone; it's a commercial accelerant.

CoverRight Releases Review of Medicare Part D Prescription Drug Costs relative to Mark Cuban Cost Plus Drug Company, PBC

Retrieved on: 
Wednesday, October 11, 2023
Cost Plus Drugs, Health, Medicare, Medicare Part D, PBC, Doctor of Philosophy, Ageing, Prescription, Elijah Cummings Lower Drug Costs Now Act, Plasma protein binding, Health insurance, Pharmaceutical industry

NEW YORK, Oct. 11, 2023 /PRNewswire-PRWeb/ -- CoverRight, a digital-first concierge platform designed to empower older adults and their families to easily learn about and navigate Medicare health insurance online is pleased to release a review comparing Medicare Part D drug costs to purchasing prescriptions through Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs).

Key Points: 
  • CoverRight, a digital-first concierge platform designed to empower older adults and their families to easily learn about and navigate Medicare health insurance online is pleased to release a review comparing Medicare Part D drug costs to purchasing prescriptions through Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs).
  • NEW YORK, Oct. 11, 2023 /PRNewswire-PRWeb/ -- CoverRight , a digital-first concierge platform designed to empower older adults and their families to easily learn about and navigate Medicare health insurance online is pleased to release a review comparing Medicare Part D drug costs to purchasing prescriptions through Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs).
  • CoverRight is the first digital Medicare selection platform to integrate Cost Plus Drugs data into its platform, allowing consumers to compare and save on prescription drug costs.
  • This review builds upon CoverRight and Cost Plus Drugs' successful collaboration initiated in October 2022 to help Medicare beneficiaries save additionally on drug costs.

New Report by Parsley Health Pulls Back the Curtain on the State of Health of Women in the Workforce, Reveals Top Concerns – and Opportunities – for Employers

Retrieved on: 
Tuesday, October 3, 2023
Women, Human Resources, General Health, Health, Mental Health, Professional Services, Consumer, Other Health, Workforce, Medical Affairs Bureau, Headache, Woman, Prescription, Research, Plasma protein binding, Momentive (software company), TME, Diagnosis, Mental health, Fatigue, Medical device, Pharmaceutical industry, Nursing, Momentive

Fractured care keeps women in a revolving door of prescription drugs, specialist referrals, and delayed diagnosis – and they want out.

Key Points: 
  • Fractured care keeps women in a revolving door of prescription drugs, specialist referrals, and delayed diagnosis – and they want out.
  • “Symptoms and comorbidities for this population are often interrelated and point to bigger, chronic health issues.
  • Parsley Health partnered with SurveyMonkey, a subsidiary of Momentive, to administer the online survey, conducted July 5 - 8, 2023.
  • At the time of the survey, all respondents were employed full-time, had health insurance, and identified as women.